High Intensity Training for Neurological Injury Using Overground Exoskeletons in Inpatient Rehabilitation (HIT Exo IP)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04973852 |
Recruitment Status :
Recruiting
First Posted : July 22, 2021
Last Update Posted : January 21, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Spinal Cord Injuries | Device: Ekso | Not Applicable |
The purpose of this study is to determine the feasibility and potential efficacy to implement high cardiovascular intensity training parameters (70-80% heart rate reserve) with the use of overground wearable robotic exoskeletons in an inpatient rehabilitation setting for locomotor recovery.
The second aim is to investigate the potential functional improvements in gait after receiving high-intensity locomotor training with an overground exoskeleton, as measured on the 10-meter walk test and six-minute walk test.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 20 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | High Intensity Training for Neurological Injury Using Overground Exoskeletons in Inpatient Rehabilitation |
Actual Study Start Date : | August 6, 2021 |
Estimated Primary Completion Date : | August 31, 2023 |
Estimated Study Completion Date : | August 31, 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Exoskeleton
5 sessions of overground ambulation with wearable exoskeleton where heart rate is monitored over each session.
|
Device: Ekso
Exoskeleton walking |
- Percentage of Heart Rate Reserve Achieved During HIT Gait Training Session while Wearing Exoskeleton [ Time Frame: During session 1 (about day 2) ]Heart rate will be monitored continuously and recorded every 5 minutes throughout the session (each session lasts about 60 minutes). Heart rate reserve (HRR) is maximum heart rate (HRmax) minus resting heart rate (HRrest). Target HR ranges will be calculated using age-predicted maximum heart rate (HRmax = 208 - {0.7 * age]) and Karvonen formula (target HRR (70%) = ([0.7 * (HRmax - HRrest)] + HRrest) and (target HRR (80%) = (0.8 * (HRmax - HRrest)] + HRrest). The percentage of HRR achieved during the exoskeleton session is calculated as the percentage of HR readings during the session that are within the 70-80% target HR zone.
- Percentage of Heart Rate Reserve Achieved During HIT Gait Training Session [ Time Frame: During session 2 (about day 4) ]Heart rate will be monitored continuously and recorded every 5 minutes throughout the session (each session lasts about 60 minutes). Heart rate reserve (HRR) is maximum heart rate (HRmax) minus resting heart rate (HRrest). Target HR ranges will be calculated using age-predicted maximum heart rate (HRmax = 208 - {0.7 * age]) and Karvonen formula (target HRR (70%) = ([0.7 * (HRmax - HRrest)] + HRrest) and (target HRR (80%) = (0.8 * (HRmax - HRrest)] + HRrest). The percentage of HRR achieved during the exoskeleton session is calculated as the percentage of HR readings during the session that are within the 70-80% target HR zone.
- Percentage of Heart Rate Reserve Achieved During HIT Gait Training Session [ Time Frame: During session 3 (about day 6) ]Heart rate will be monitored continuously and recorded every 5 minutes throughout the session (each session lasts about 60 minutes). Heart rate reserve (HRR) is maximum heart rate (HRmax) minus resting heart rate (HRrest). Target HR ranges will be calculated using age-predicted maximum heart rate (HRmax = 208 - {0.7 * age]) and Karvonen formula (target HRR (70%) = ([0.7 * (HRmax - HRrest)] + HRrest) and (target HRR (80%) = (0.8 * (HRmax - HRrest)] + HRrest). The percentage of HRR achieved during the exoskeleton session is calculated as the percentage of HR readings during the session that are within the 70-80% target HR zone.
- Percentage of Heart Rate Reserve Achieved During HIT Gait Training Session [ Time Frame: During session 4 (about day 9) ]Heart rate will be monitored continuously and recorded every 5 minutes throughout the session (each session lasts about 60 minutes). Heart rate reserve (HRR) is maximum heart rate (HRmax) minus resting heart rate (HRrest). Target HR ranges will be calculated using age-predicted maximum heart rate (HRmax = 208 - {0.7 * age]) and Karvonen formula (target HRR (70%) = ([0.7 * (HRmax - HRrest)] + HRrest) and (target HRR (80%) = (0.8 * (HRmax - HRrest)] + HRrest). The percentage of HRR achieved during the exoskeleton session is calculated as the percentage of HR readings during the session that are within the 70-80% target HR zone.
- Percentage of Heart Rate Reserve Achieved During HIT Gait Training Session [ Time Frame: During session 5 (about day 11) ]Heart rate will be monitored continuously and recorded every 5 minutes throughout the session (each session lasts about 60 minutes). Heart rate reserve (HRR) is maximum heart rate (HRmax) minus resting heart rate (HRrest). Target HR ranges will be calculated using age-predicted maximum heart rate (HRmax = 208 - {0.7 * age]) and Karvonen formula (target HRR (70%) = ([0.7 * (HRmax - HRrest)] + HRrest) and (target HRR (80%) = (0.8 * (HRmax - HRrest)] + HRrest). The percentage of HRR achieved during the exoskeleton session is calculated as the percentage of HR readings during the session that are within the 70-80% target HR zone.
- Change in Self Selected Gait Speed as Assessed by the 10 Meter Walk Test (10MWT) [ Time Frame: Pre Intervention (about 1 day prior to intervention) and 1 Day after session 5 (about day 12) ]During the 10 Meter Walk Test, four marks will be placed on the ground at 0,2,12 and 14 meters. Subjects will walk a total of 14 meters, where the middle 10 meters (between marks 2 and 12 meters) will be timed and recorded as their gait speed. Subjects will complete two attempts at their self-selected pace. The two trials will be averaged and reported as self-selected speed.
- Change in Fast Gait Speed as Assessed by the 10 Meter Walk Test (10MWT) [ Time Frame: Pre Intervention (about 1 day prior to intervention) and 1 Day after session 5 (about day 12) ]During the 10 Meter Walk Test, four marks will be placed on the ground at 0,2,12 and 14 meters. Subjects will walk a total of 14 meters, where the middle 10 meters (between marks 2 and 12 meters) will be timed and recorded as their gait speed. Subjects will complete two attempts at their fastest pace. The two trials will be averaged and reported as fast gait speed.
- Change in Walking Endurance as Assessed by the 6 Minute Walk Test (6MWT) [ Time Frame: Pre Intervention (about 1 day prior to intervention) and 1 Day after session 5 (about day 12) ]The 6 Minute Walk Test will measure the distance subjects can walk over six minutes. Subjects will walk along a 100-foot hallway as many times as they can in 6 minutes. Subjects are allowed to rest as needed; however, the timer continues to run for 6 minutes consecutively, whether they are standing or walking.
- Change in Seated Dynamic Reach as Assessed by the Modified Functional Reach Test [ Time Frame: Pre Intervention (about 1 day prior to intervention) and 1 Day after session 5 (about day 12) ]The Modified Functional Reach Test measures the maximum distance an individual can reach forward from a seated position. This will be reported as an average of three trials.
- Change in Spatial-Temporal Gait Parameters as assessed by the GAITRite pressure map (step length parameter) [ Time Frame: Pre Intervention (about 1 day prior to intervention) and 1 Day after session 5 (about day 12) ]The GAITRite pressure map will be used during the 10MWT. This pressure map will digitally record the subject's footprints' placement and pressure as they walk over it during the 10MWT. This assessment will indicate several temporospatial gait parameters. The average step length (measured in centimeters) will be reported.
- Change in Spatial-Temporal Gait Parameters as assessed by the GAITRite pressure map (stride length parameter) [ Time Frame: Pre Intervention (about 1 day prior to intervention) and 1 Day after session 5 (about day 12) ]The GAITRite pressure map will be used during the 10MWT. This pressure map will digitally record the subject's footprints' placement and pressure as they walk over it during the 10MWT. This assessment will indicate several temporospatial gait parameters. The average stride length (measured in centimeters) will be reported.
- Change in Spatial-Temporal Gait Parameters as assessed by the GAITRite pressure map (single support parameter) [ Time Frame: Pre Intervention (about 1 day prior to intervention) and 1 Day after session 5 (about day 12) ]The GAITRite pressure map will be used during the 10MWT. This pressure map will digitally record the subject's footprints' placement and pressure as they walk over it during the 10MWT. This assessment will indicate several temporospatial gait parameters. The average time spent in single limb support (measured as percentage of total gait cycle) will be reported.
- Change in Spatial-Temporal Gait Parameters as assessed by the GAITRite pressure map (double support parameter) [ Time Frame: Pre Intervention (about 1 day prior to intervention) and 1 Day after session 5 (about day 12) ]The GAITRite pressure map will be used during the 10MWT. This pressure map will digitally record the subject's footprints' placement and pressure as they walk over it during the 10MWT. This assessment will indicate several temporospatial gait parameters. The average time spent in double limb support (measured as percentage of total gait cycle) will be reported.
- Change in Spatial-Temporal Gait Parameters as assessed by the GAITRite pressure map (swing time parameter) [ Time Frame: Pre Intervention (about 1 day prior to intervention) and 1 Day after session 5 (about day 12) ]The GAITRite pressure map will be used during the 10MWT. This pressure map will digitally record the subject's footprints' placement and pressure as they walk over it during the 10MWT. This assessment will indicate several temporospatial gait parameters. The average time spent in swing phase (measured as percentage of total gait cycle) will be reported.
- Change in Spatial-Temporal Gait Parameters as assessed by the GAITRite pressure map (stance time parameter) [ Time Frame: Pre Intervention (about 1 day prior to intervention) and 1 Day after session 5 (about day 12) ]The GAITRite pressure map will be used during the 10MWT. This pressure map will digitally record the subject's footprints' placement and pressure as they walk over it during the 10MWT. This assessment will indicate several temporospatial gait parameters. The average time spent in stance phase (measured as percentage of total gait cycle) will be reported.
- Change in Spatial-Temporal Gait Parameters as assessed by the GAITRite pressure map (heel to heel base of support time parameter) [ Time Frame: Pre Intervention (about 1 day prior to intervention) and 1 Day after session 5 (about day 12) ]The GAITRite pressure map will be used during the 10MWT. This pressure map will digitally record the subject's footprints' placement and pressure as they walk over it during the 10MWT. This assessment will indicate several temporospatial gait parameters. The average heel to heel base of support (measured in centimeters) will be reported.
- Change in Metabolic Expenditure during 10MWT, as Assessed by Oxygen Consumption [ Time Frame: Pre Intervention (about 1 day prior to intervention) and 1 Day after session 5 (about day 12) ]Change in metabolic expenditure during 10MWT will be indicated by energy expenditure. Energy Expenditure will be measured by the K4 b2 Cosmed as follows: Oxygen cost will be calculated from oxygen consumption as the product of gait speed and body weight. Oxygen consumption will be collected on a breath-by-breath basis measured by a portable metabolic system (K4 b2 Cosmed). Prior to the testing, the system will be calibrated using room air and reference gas mixture. During the testing, the subject will wear a face mask and a heart rate monitor at all times and will be asked to breathe normally. The average oxygen cost will be reported as VO2 peak during 10MWT.
- Change in Metabolic Expenditure during 6MWT, as Assessed by Oxygen Consumption [ Time Frame: Pre Intervention (about 1 day prior to intervention) and 1 Day after session 5 (about day 12) ]Change in metabolic expenditure during 6MWT will be indicated by energy expenditure. Energy Expenditure will be measured by the K4 b2 Cosmed as follows: Oxygen cost will be calculated from oxygen consumption as the product of gait speed and body weight. Oxygen consumption will be collected on a breath-by-breath basis measured by a portable metabolic system (K4 b2 Cosmed). Prior to the testing, the system will be calibrated using room air and reference gas mixture. During the testing, the subject will wear a face mask and a heart rate monitor at all times and will be asked to breathe normally. The average oxygen cost will be reported as VO2 peak during 6MWT.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Able to achieve adequate fit within the exoskeleton
- Diagnosis of motor incomplete SCI (AIS C or D)
- Sufficient range of motion to attain normal, reciprocal gait pattern, and transition from normal sit to stand or stand to sit
- Intact skin on all surfaces in contact with device and load-bearing surfaces
- Weight <220 pounds
Exclusion Criteria:
- Pregnancy
- Spinal instability
- Unhealed limb or pelvic fractures or any condition restricting weight-bearing in limbs
- Diagnosis of other neurological injuries other than SCI
- Uncontrolled spasticity (≥3 on Modified Ashworth Scale)
- Colostomy
- Decreased range of motion or contractures in legs (>10° at hips, knees, or ankles)
- Uncontrolled autonomic dysreflexia
- Unresolved deep vein thrombosis
- Inability to tolerate standing due to cardiovascular issues or orthostatic hypotension
- Inability to follow 3 step commands
- Severe comorbidities: active infections, heart, lung, or circulatory conditions
- Pressure sores, impaired skin integrity
- Use of mechanical ventilation for respiratory support

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04973852
Contact: Shuo-Hsiu (James) Chang | 713-799-7016 | shuo-hsiu.chang@uth.tmc.edu | |
Contact: Marcie Kern | 713-799-6995 | marcia.kern@uth.tmc.edu |
United States, Texas | |
NeuroRecovery Research Center at TIRR Memorial Hermann | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: James Chang |
Principal Investigator: | Shuo-Hsiu (James) Chang | The University of Texas Health Sciences Center at Houston |
Responsible Party: | Shuo-Hsiu Chang, Assistant Professor, The University of Texas Health Science Center, Houston |
ClinicalTrials.gov Identifier: | NCT04973852 |
Other Study ID Numbers: |
HSC-MS-21-0262 |
First Posted: | July 22, 2021 Key Record Dates |
Last Update Posted: | January 21, 2022 |
Last Verified: | January 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | Yes |
spinal cord injury high intensity exoskeleton |
Spinal Cord Injuries Trauma, Nervous System Wounds and Injuries |
Spinal Cord Diseases Central Nervous System Diseases Nervous System Diseases |